Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Chunxia SU; Caicun ZHOU

doi:10.19401/j.cnki.1007-3639.2022.06.002

您当前的位置：

首页 >

文章列表页 >

Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Specialists' Commentary | 更新时间：2025-12-31

- Current status and future directions of immunotherapy for advanced non-small cell lung cancer
- China Oncology Vol. 32, Issue 6, Pages: 478-486(2022)
- 作者机构：
  
  同济大学附属上海市肺科医院肿瘤科,上海 200433
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.06.002
  CLC： R734.2
- Received：27 May 2022，
  
  Revised：2022-06-10，
  
  Published：30 June 2022
- 稿件说明：
移动端阅览
Chunxia SU, Caicun ZHOU. Current status and future directions of immunotherapy for advanced non-small cell lung cancer[J]. China Oncology, 2022, 32(6): 478-486.
DOI：

Chunxia SU, Caicun ZHOU. Current status and future directions of immunotherapy for advanced non-small cell lung cancer[J]. China Oncology, 2022, 32(6): 478-486. DOI： 10.19401/j.cnki.1007-3639.2022.06.002.

摘要

肺癌仍然是中国发病率和死亡率最高的恶性肿瘤

其中非小细胞肺癌（non-small cell lung cancer

NSCLC）约占80%以上。以靶向程序性死亡[蛋白]-1（programmed death protein-1

PD-1）或程序性死亡[蛋白]配体-1（programmed death ligand-1

PD-L1）的免疫检查点抑制剂（immune checkpoint inhibitor

ICI）为基础的治疗已成为了晚期肺癌的标准治疗手段之一。本综述将对晚期NSCLC免疫治疗的现状予以梳理

探讨现阶段面临的问题与挑战

并思考与展望未来发展方向。

Abstract

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China

among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1 (PD-L1) has become one of the standard treatments for advanced NSCLC. This review

with the focus on advanced NSCLC

summarized the development of immunotherapy

discussed current problems

and challenges and proposed future directions.

关键词

Keywords

references

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

MOLINA J R , YANG P , CASSIVI S D , et al . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J ] . Mayo Clin Proc , 2008 , 83 ( 5 ): 584 - 594 . DOI: 10.1016/S0025-6196(11)60735-0 http://doi.org/10.1016/S0025-6196(11)60735-0 https://linkinghub.elsevier.com/retrieve/pii/S0025619611607350 https://linkinghub.elsevier.com/retrieve/pii/S0025619611607350

YANG C Y , YANG J C H , YANG P C . Precision management of advanced non-small cell lung cancer [J ] . Annu Rev Med , 2020 , 71 : 117 - 136 . DOI: 10.1146/annurev-med-051718-013524 http://doi.org/10.1146/annurev-med-051718-013524 https://www.annualreviews.org/doi/10.1146/annurev-med-051718-013524 https://www.annualreviews.org/doi/10.1146/annurev-med-051718-013524

RECK M , RODRÍGUEZ-ABREU D , ROBINSON A G , et al . Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1823 - 1833 . DOI: 10.1056/NEJMoa1606774 http://doi.org/10.1056/NEJMoa1606774 http://www.nejm.org/doi/10.1056/NEJMoa1606774 http://www.nejm.org/doi/10.1056/NEJMoa1606774

BRAHMER J R , RODRIGUEZ-ABREU D , ROBINSON A G , et al. LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) & #x02265;50% [J ] . Ann Oncol , 2020 , 31 : S1181-S1182.

HERBST R S , GIACCONE G , DE MARINIS F , et al . Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC [J ] . N Engl J Med , 2020 , 383 ( 14 ): 1328 - 1339 . DOI: 10.1056/NEJMoa1917346 http://doi.org/10.1056/NEJMoa1917346 http://www.nejm.org/doi/10.1056/NEJMoa1917346 http://www.nejm.org/doi/10.1056/NEJMoa1917346

JASSEM J , DE MARINIS F , GIACCONE G , et al . Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 11 ): 1872 - 1882 . DOI: 10.1016/j.jtho.2021.06.019 http://doi.org/10.1016/j.jtho.2021.06.019 https://linkinghub.elsevier.com/retrieve/pii/S1556086421022863 https://linkinghub.elsevier.com/retrieve/pii/S1556086421022863

SEZER A , KILICKAP S , GÜMÜŞ M , et al . Cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial [J ] . Lancet , 2021 , 397 ( 10274 ): 592 - 604 . DOI: 10.1016/S0140-6736(21)00228-2 http://doi.org/10.1016/S0140-6736(21)00228-2 https://linkinghub.elsevier.com/retrieve/pii/S0140673621002282 https://linkinghub.elsevier.com/retrieve/pii/S0140673621002282

RECK M , RODRÍGUEZ-ABREU D , ROBINSON A G , et al . Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50 [J ] . J Clin Oncol , 2021 , 39 ( 21 ): 2339 - 2349 . DOI: 10.1200/JCO.21.00174 http://doi.org/10.1200/JCO.21.00174 https://ascopubs.org/doi/10.1200/JCO.21.00174 https://ascopubs.org/doi/10.1200/JCO.21.00174

HWANG D M , ALBAQER T , SANTIAGO R C , et al . Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer [J ] . J Thorac Oncol , 2021 , 16 ( 9 ): 1490 - 1500 . DOI: 10.1016/j.jtho.2021.03.028 http://doi.org/10.1016/j.jtho.2021.03.028 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021080 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021080

GANDHI L , RODRÍGUEZ-ABREU D , GADGEEL S , et al . Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer [J ] . N Engl J Med , 2018 , 378 ( 22 ): 2078 - 2092 . DOI: 10.1056/NEJMoa1801005 http://doi.org/10.1056/NEJMoa1801005 http://www.nejm.org/doi/10.1056/NEJMoa1801005 http://www.nejm.org/doi/10.1056/NEJMoa1801005

GADGEEL S , GARASSINO M C , ESTEBAN E , et al . KEYNOTE-189: OS update and progression after the next line of therapy (PFS2) with pembrolizumab + chemotherapy for metastatic nonsquamous NSCLC [J ] . J Thorac Oncol , 2019 , 14 ( 11 ): S1153 .

PAZ-ARES L , LUFT A , VICENTE D , et al . Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 21 ): 2040 - 2051 . DOI: 10.1056/NEJMoa1810865 http://doi.org/10.1056/NEJMoa1810865 http://www.nejm.org/doi/10.1056/NEJMoa1810865 http://www.nejm.org/doi/10.1056/NEJMoa1810865

PAZ-ARES L , VICENTE D , TAFRESHI A , et al . A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407 [J ] . J Thorac Oncol , 2020 , 15 ( 10 ): 1657 - 1669 . DOI: 10.1016/j.jtho.2020.06.015 http://doi.org/10.1016/j.jtho.2020.06.015 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305001 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305001

ZHOU C C , CHEN G Y , HUANG Y C , et al . Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet Respir Med , 2021 , 9 ( 3 ): 305 - 314 . DOI: 10.1016/S2213-2600(20)30365-9 http://doi.org/10.1016/S2213-2600(20)30365-9 https://linkinghub.elsevier.com/retrieve/pii/S2213260020303659 https://linkinghub.elsevier.com/retrieve/pii/S2213260020303659

YANG Y P , WANG Z H , FANG J , et al . Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology program by innovent anti-PD-1-11) [J ] . J Thorac Oncol , 2020 , 15 ( 10 ): 1636 - 1646 . DOI: 10.1016/j.jtho.2020.07.014 http://doi.org/10.1016/j.jtho.2020.07.014 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305955 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305955

YANG Y P , SUN J Y , WANG Z H , et al . Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study [J ] . J Thorac Oncol , 2021 , 16 ( 12 ): 2109 - 2120 . DOI: 10.1016/j.jtho.2021.07.015 http://doi.org/10.1016/j.jtho.2021.07.015 https://linkinghub.elsevier.com/retrieve/pii/S1556086421023303 https://linkinghub.elsevier.com/retrieve/pii/S1556086421023303

LU S , WANG J , YU Y , et al . Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial [J ] . J Thorac Oncol , 2021 , 16 ( 9 ): 1512 - 1522 . DOI: 10.1016/j.jtho.2021.05.005 http://doi.org/10.1016/j.jtho.2021.05.005 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021766 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021766

ZHOU C , REN S , CHEN J , et al . Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): a randomized, double-blind, multicenter, phase Ⅲ trial [J ] . J Thorac Oncol , 2021 , 16 ( 4 ): S748.

WANG J , LU S , HU C , et al . Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC) [J ] . Ann Oncol , 2020 , 31 : S817.

ZHOU C C , WU L , FAN Y , et al . Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12) [J ] . J Thorac Oncol , 2021 , 16 ( 9 ): 1501 - 1511 . DOI: 10.1016/j.jtho.2021.04.011 http://doi.org/10.1016/j.jtho.2021.04.011 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021286 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021286

ZHOU C C , WANG Z P , SUN Y P , et al . Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial [J ] . Lancet Oncol , 2022 , 23 ( 2 ): 220 - 233 . DOI: 10.1016/S1470-2045(21)00650-1 http://doi.org/10.1016/S1470-2045(21)00650-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204521006501 https://linkinghub.elsevier.com/retrieve/pii/S1470204521006501

WANG J , WANG Z , WU L , et al . CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): S927-S928 .

RECK M , JOTTE R , CAPPUZZO F , et al . IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets) [J ] . Pneumologie , 2020 , 74 : S39-S39

YANG J C H , LUFT A , DE LA MORA JIMÉNEZ E , et al . Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): a phase Ⅲ, randomized, double-blind study [J ] . Ann Oncol , 2021 , 32 : S1429-S1430.

NISHIO M , PELED N , ZER A , et al . Phase Ⅲ LEAP-006 safety Run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC [J ] . Ann Oncol , 2020 , 31 : S848-S849.

REN S X , HE J X , FANG Y , et al . Camrelizumab plus apatinib in treatment-naive patients with advanced nonsquamous NSCLC: a multicenter, open-label, single-arm, phase 2 trial [J ] . JTO Clin Res Rep , 2022 , 3 ( 5 ): 100312 .

HAN B H , CHEN J , XIE Q , et al . A multicenter, randomized, phase 3 trial of penpulimab in combination with anlotinib or chemotherapy as first-line treatment in advanced NSCLC [J ] . J Thorac Oncol Off Publ Int Assoc Study Lung Cancer , 2021 , 16 ( 3 ): S650.

CHU T Q , ZHONG R B , ZHONG H , et al . Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 4 ): 643 - 652 . DOI: 10.1016/j.jtho.2020.11.026 http://doi.org/10.1016/j.jtho.2020.11.026 https://linkinghub.elsevier.com/retrieve/pii/S1556086420311011 https://linkinghub.elsevier.com/retrieve/pii/S1556086420311011

ZHAO S , REN S X , JIANG T , et al . Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer [J ] . Cancer Immunol Res , 2019 , 7 ( 4 ): 630 - 643 . DOI: 10.1158/2326-6066.CIR-17-0640 http://doi.org/10.1158/2326-6066.CIR-17-0640 https://aacrjournals.org/cancerimmunolres/article/7/4/630/469459/Low-Dose-Apatinib-Optimizes-Tumor-Microenvironment https://aacrjournals.org/cancerimmunolres/article/7/4/630/469459/Low-Dose-Apatinib-Optimizes-Tumor-Microenvironment

HELLMANN M D , PAZ-ARES L , BERNABE CARO R , et al . Nivolumab plus ipilimumab in advanced non-small cell lung cancer [J ] . N Engl J Med , 2019 , 381 ( 21 ): 2020 - 2031 . DOI: 10.1056/NEJMoa1910231 http://doi.org/10.1056/NEJMoa1910231 http://www.nejm.org/doi/10.1056/NEJMoa1910231 http://www.nejm.org/doi/10.1056/NEJMoa1910231

PAZ-ARES L G , RAMALINGAM S S , CIULEANU T E , et al . First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial [J ] . J Thorac Oncol , 2022 , 17 ( 2 ): 289 - 308 . DOI: 10.1016/j.jtho.2021.09.010 http://doi.org/10.1016/j.jtho.2021.09.010 https://linkinghub.elsevier.com/retrieve/pii/S155608642103207X https://linkinghub.elsevier.com/retrieve/pii/S155608642103207X

PAZ-ARES L , CIULEANU T E , COBO M , et al . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 2 ): 198 - 211 . DOI: 10.1016/S1470-2045(20)30641-0 http://doi.org/10.1016/S1470-2045(20)30641-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410 https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410

JOHN T , SAKAI H , IKEDA S , et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA [J ] . Ann Oncol , 2020 , 31 : S847-S848.

JOHNSON M , CHO B C , LUFT A , et al . Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): S844.

ABREU D R , RECK M , ŞENDUR N , et al . Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up [J ] . Ann Oncol , 2022 , 33 : S30-S31.

MARUHASHI T , SUGIURA D , OKAZAKI I M , et al . LAG-3: from molecular functions to clinical applications [J ] . J Immunother Cancer , 2020 , 8 ( 2 ): e001014.

HODI F S , TAWBI H A , LIPSON E J , et al . Relatlimab (RELA) + nivolumab (NIVO) vs NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIV ITY-047 [J ] . Ann Oncol , 2021 , 32 : S867-S868.

MORGENSZTERN D , CHAUDHRY A , IANNOTTI N , et al . RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs NIVO with chemotherapy in stage & #x02163; or recurrent non-small cell lung cancer (NSCLC): a phase & #x02161;, randomized, double-blind study [J ] . Ann Oncol , 2021 , 32 : S1030.

CHAUVIN J M , ZAROUR H M . TIGIT in cancer immunotherapy [J ] . J Immunother Cancer , 2020 , 8 ( 2 ): e000957.

CHO B C , ABREU D R , HUSSEIN M , et al . Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study [J ] . Lancet Oncol , 2022 , 23 ( 6 ): 781 - 792 . DOI: 10.1016/S1470-2045(22)00226-1 http://doi.org/10.1016/S1470-2045(22)00226-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204522002261 https://linkinghub.elsevier.com/retrieve/pii/S1470204522002261

MARIN-ACEVEDO J A , KIMBROUGH E O , LOU Y Y . Next generation of immune checkpoint inhibitors and beyond [J ] . J Hematol Oncol , 2021 , 14 ( 1 ): 45 . DOI: 10.1186/s13045-021-01056-8 http://doi.org/10.1186/s13045-021-01056-8 https://doi.org/10.1186/s13045-021-01056-8 https://doi.org/10.1186/s13045-021-01056-8

PAZ-ARES L , KIM T M , VICENTE D , et al . Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial [J ] . J Thorac Oncol , 2020 , 15 ( 7 ): 1210 - 1222 . DOI: 10.1016/j.jtho.2020.03.003 http://doi.org/10.1016/j.jtho.2020.03.003 https://linkinghub.elsevier.com/retrieve/pii/S1556086420301957 https://linkinghub.elsevier.com/retrieve/pii/S1556086420301957

WU L , CHEN B , YAO W , et al . A phase Ⅰb/Ⅱ trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC [J ] . Ann Oncol , 2021 , 32 : S1006.

HONG M H , CLUBB J D , CHEN Y Y . Engineering CAR-T cells for next-generation cancer therapy [J ] . Cancer Cell , 2020 , 38 ( 4 ): 473 - 488 . DOI: 10.1016/j.ccell.2020.07.005 http://doi.org/10.1016/j.ccell.2020.07.005 https://linkinghub.elsevier.com/retrieve/pii/S1535610820303664 https://linkinghub.elsevier.com/retrieve/pii/S1535610820303664

QU J J , MEI Q H , CHEN L J , et al . Chimeric antigen receptor (CAR)-T-cell therapy in non-small cell lung cancer (NSCLC): current status and future perspectives [J ] . Cancer Immunol Immunother , 2021 , 70 ( 3 ): 619 - 631 . DOI: 10.1007/s00262-020-02735-0 http://doi.org/10.1007/s00262-020-02735-0 https://doi.org/10.1007/s00262-020-02735-0 https://doi.org/10.1007/s00262-020-02735-0

YILMAZ A , CUI H W , CALIGIURI M A , et al . Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 168 . DOI: 10.1186/s13045-020-00998-9 http://doi.org/10.1186/s13045-020-00998-9 https://doi.org/10.1186/s13045-020-00998-9 https://doi.org/10.1186/s13045-020-00998-9

GOULDING J , BLUM R , HANCOCK B , et al . Abstract 1591: FT536: preclinical development of a novel off-the-shelf CAR-MICA/B NK cell immunotherapy combined with radiation and antibody treatments as a first-of-kind pan-cancer targeting strategy [J ] . Cancer Res , 2021 , 81 ( 13_Supplement ): 1591 . DOI: 10.1158/1538-7445.AM2021-1591 http://doi.org/10.1158/1538-7445.AM2021-1591 https://aacrjournals.org/cancerres/article/81/13_Supplement/1591/667388/Abstract-1591-FT536-Preclinical-development-of-a https://aacrjournals.org/cancerres/article/81/13_Supplement/1591/667388/Abstract-1591-FT536-Preclinical-development-of-a

HEMMINKI O , DOS SANTOS J M , HEMMINKI A . Oncolytic viruses for cancer immunotherapy [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 84 . DOI: 10.1186/s13045-020-00922-1 http://doi.org/10.1186/s13045-020-00922-1 https://doi.org/10.1186/s13045-020-00922-1 https://doi.org/10.1186/s13045-020-00922-1

SAXENA M , VAN DER BURG S H , MELIEF C J M , et al . Therapeutic cancer vaccines [J ] . Nat Rev Cancer , 2021 , 21 ( 6 ): 360 - 378 . DOI: 10.1038/s41568-021-00346-0 http://doi.org/10.1038/s41568-021-00346-0 https://doi.org/10.1038/s41568-021-00346-0 https://doi.org/10.1038/s41568-021-00346-0

Views

7479

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors

Important clinical research progress in lung cancer in 2022

Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects

Related Author

Ye GUO

Chaosu HU

Chenping ZHANG

Yuyang ZHANG

Qian LIU

Yingyun LIANG

Jianhua CHEN

Chunxia SU

Related Institution

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

School of Basic Medical Sciences, Shanghai Medical College, Fudan University

AI问答

⁰